|Bid||4.2300 x 21500|
|Ask||4.2800 x 3200|
|Day's range||4.0900 - 4.4600|
|52-week range||1.9700 - 7.1000|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2020 - 07 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.60|
Endo International plc Announces Early Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations
At this time, I would like to welcome everyone to the Q1 2020 Endo International earnings conference call. Joining me on today's call are Blaise Coleman, president and CEO of Endo; Mark Bradley, executive vice president and CFO; and Pat Barry, president, global commercial operations; and Domenic Ciarico, chief commercial officer of sterile injectables and generics.
Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic
Endo (ENDP) delivered earnings and revenue surprises of 75.93% and 14.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Endo Reports First-Quarter 2020 Financial Results and Provides Update Relating to COVID-19 Pandemic
A billion-dollar market opportunity exists for an opioid manufacturer plagued with lawsuits, but will it be enough for a comeback?
DUBLIN , Feb. 19, 2020 /CNW/ -- Endo International plc (ENDP) today announced that Blaise Coleman , who has served as the Company's Executive Vice President and Chief Financial Officer since 2016, will succeed Paul Campanelli as President and Chief Executive Officer and will become a member of the Board of Directors effective March 6, 2020 . Mr. Campanelli will continue to serve as Chairman of the Board. This appointment will complete the Chief Executive Officer succession plan that Endo announced in November 2019 .
The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.
Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States
A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.
The state of Oklahoma will receive $8.75 million from two pharmaceutical companies in a deal announced Friday that will end legal action the state was considering against the opioid manufacturers. Oklahoma Attorney General Mike Hunter announced the agreement with Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc., both subsidiaries of Dublin-based Endo International. Without the agreement, Hunter said he planned to file suit against the company alleging it violated state law by deceptively marketing opioid pain medications in a way that understated the risk of addiction.
DUBLIN , Jan. 10, 2020 /CNW/ -- Endo International plc (ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. (collectively, the "Settling Parties") have executed a Settlement Agreement with the State of Oklahoma (" Oklahoma "). The Settlement Agreement fully and finally resolves Oklahoma's investigation of the Settling Parties in connection with the opioid abuse crisis in Oklahoma and includes a release of all associated claims by Oklahoma to the Settling Parties and all of their affiliated entities and persons (collectively, the "Endo Affiliates").